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between the three transplant groups appeared in the ﬁrst 100 days
post transplant but without giving advantage to any group. Indeed,
the delay of engraftment and increased treatment-related mortality
observed after UCBT must be balanced with the higher risk of
acute GVHD after unmanipulated BMT and with the higher risk
of relapse after T-cell depleted BMT. In contrast, after day 100
posttransplant, the 3 groups achieved similar results in terms of
relapse but chronic GVHD and death occurred more frequently
with unmanipulated BMT and T-cell depleted BMT respectively.
These results justify the simultaneous search for unrelated cord
blood and unrelated bone marrow donors for children with acute
leukemia. The decision to perform cord blood transplants will be
based on the cell content of the graft, the number of HLA dispar-
ities and the urgency of the transplant.
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UNRELATED CORD BLOOD TRANSPLANTATION FOR TRANSFUSION-
DEPENDENT THALASSEMIA IN CHILDREN
Jaing, T.H., Hung, I.J., Yang, C.P. Chang Gung Children’s Hospital,
Chang Gung University, Taoyuan, Taiwan
Hematopoietic stem cell transplantation is currently the only
curative therapy for transfusion-dependent thalassemia. However,
approximately 30% of patients have unaffected HLA-identical sib-
lings to serve as donors. We investigated the feasibility of unrelated
cord blood transplantation (CBT) as a potential strategy for aug-
menting the pool of acceptable donors. Between October 2003 and
December 2004, 9 children with 	-thalassemia major received
CBT with at least 2.5  107/kg TNC from unrelated donors (0-2
of 6 HLA antigens were mismatched) and were then evaluated for
engraftment, adverse effects, and treatment outcome. Condition-
ing consisted of busulfan, cyclophosphamide, and antithymocyte
globulin, and GVHD prophylaxis of cyclosporine and methylpred-
nisolone. Median age was 3.7 years (range, 2.3-11.4 years). One
patient died of penicillin-resistant S. mitis sepsis at day 8 prior to
the “expected” time to respond. Eight of 9 patients were alive at
median follow-up of 254 days after transplantation, with complete
donor chimerism and transfusion independence. The median times
to neutrophil engraftment, RBC transfusion independence, and
platelet engraftment were 13, 34, and 45 days after transplantation,
respectively. The patients showed grade I-III acute GVHD. No
extensive chronic GVHD had developed at the latest contact. The
medical costs per-patient with CBT in Taiwan is estimated to be
approximately US$40,000 plus the cost of the cord blood unit. In
summary, our results suggest that unrelated CBT is an alternative
treatment for patients with transfusion-dependent thalassemia
lacking an HLA-matched sibling bone marrow donor, and it is
clearly cost-effective when compared to conventional treatment
with blood transfusions and iron chelation therapy.
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OUTCOMES OF UNRELATED CORD BLOOD TRANSPLANTS AND ALLO-
GENEIC RELATED HEMATOPOIETIC STEM CELL TRANSPLANTS IN CHIL-
DREN WITH HIGH-RISK ACUTE LYMPHOCYTIC LEUKEMIA
Jacobsohn, D.A., Hewlett, B., Seshadri, R., Ranalli, M., Duerst, R.,
Kletzel, M. Children’s Memorial Hospital and Feinberg School of Med-
icine, Northwestern University, Chicago, IL
Background: HSCT is commonly used for pediatric ALL pa-
tients (pts) with early relapse or other high-risk features. Given
lack of matched-sibling donors and multiple advantages of UCB as
stem cell source (less GVHD, rapid availability), we compared
outcomes of pediatric ALL pts that underwent HSCT with UCB
(4-5/6 HLA) or matched-sibling transplant (6/6 HLA).
Methods: Pts included: ALL CR2 pts who relapsed 36 mos
from diagnosis and ALL CR1 pts with 1 high-risk feature (un-
favorable karyotype, poor response to induction, age 1 yr, WBC
100,000 at diagnosis). 25% of CR1 pts in both groups had 2
high-risk features. Cytoreduction (same in both groups): Pts re-
ceived TBI 150 cGy  8 (d 
10 to 
7); VP-16 1 g/m2/day (d 
6
to 
5); cyclophosphamide 60 mg/kg/day (d 
4 to 
2). GVHD
prophylaxis: CSA, short-course MTX, and ATG d1,3,5,7
(for UCB). Grafts were not T-cell depleted.
Results: There were 23 matched-sibling (20 BM/3 PBSC) and
26 UCB recipients. Both groups had equivalent high-risk factors.
Engraftment took longer in UCB recipients. TRM and GVHD
were equal in both groups. 3 yr EFS is 60% in both groups. Age,
gender, degree of HLA-matching for UCB, acute/chronic GVHD
did not affect EFS.
Conclusions: In pediatric pts with high-risk ALL in need of
HSCT, outcome of matched-sibling HSCT and UCB transplant is
equivalent with regards to TRM, GVHD, and EFS. UCB should
be considered a standard stem cell source to use in this group when
a matched sibling is not available.
Table 1.
Matched-sibling
(n  23) UCB (n  26) p
Age diagnosis
(yrs)* 2.5 (0.3-15.4) 3.9 (0.3-11.9) 0.63
Status at
HSCT (CR1) 11 (47.8%) 10 (38.5%) 0.34
Age <1 yr 7 (30.4%) 6 (23.1%) 0.56
Karyotype
(unfavorable) 8 (34.8%) 11 (42.3%) 0.79
Neutrophil
recovery (d)* 16 (13-21) 29 (21-35) <0.001
Platelet
recovery (d)* 24 (17-35) 51 (32-59) 0.011
100d TRM† 3 [13% (3-34)] 5 [19% (7-39)] 0.71
aGVHD (2-4)† 5 [22% (7-44)] 5 [19% (7-39)] 0.83
CGVHD (in at
risk)† 8 [40% (19-64)] 7 [33% (15-57)] 0.66
Relapse at 3
yrs† 5 [22% (7-44)] 4 [15% (4-35)] 0.72
3 yr EFS† 60% (40-80) 61% (42-80) 0.72
*Median (range); †% (95% CI).
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TOTAL BODY IRRADIATION, FLUDARABINE, MELPHALAN AND ALLO-
GENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR AD-
VANCED PEDIATRIC HEMATOLOGIC MALIGNANCIES
Petropoulos, D. M.D. Anderson Cancer Center, Houston, TX
The Fludarabine (F)-Melphalan (M) reduced-intensity prepara-
tive regimen has been successfully used in adults for allogeneic
hematopoietic stem cell transplant (HSCT). We evaluated the
efﬁcacy and toxicity of adding 9 Gy of total body irradiation (TBI),
in three single daily fractions of 3 Gy, to the reduced intensity
regimen of ﬂudarabine 30 mg/m2 i.v.  4 days and melphalan 140
mg/m2 i.v.  1 day in advanced pediatric hematologic malignan-
cies. GVHD prophylaxis consisted of tacrolimus and mini-meth-
otrexate. No anti-thymocyte globulin was used. Twenty-two acute
lymphoblastic leukemia (ALL), 6 acute myeloid leukemia (AML),
and 1 anaplastic large-cell lymphoma patients were transplanted.
Thirteen of these were beyond second remission, and ﬁve had prior
HSCT. Twenty-one donors were unrelated: 1-2 antigen mis-
matched cord blood (CB) for 19 patients, bone marrow in one and
peripheral blood stem cells (PBSC) in one. Three of the 8 related
donors were genotypically disparate. Oral mucositis and diarrhea
were the most common side effects seen. Twenty-seven patients
achieved neutrophil engraftment at a median of 16 days (range
11-35), and 23 had platelet engraftment (median 42 days, range
14-200). One patient had primary graft failure. Seven patients (all
with ALL) died of non-relapse causes in the ﬁrst 100 days. Six of 27
evaluable patients developed grade III-IV acute GVHD and three
chronic GVHD. Nine patients (7 with ALL) relapsed at a median
of 8 months post-transplant (range 2-54). With a median follow-up
of 55 (range 25-88) months, 7 of 22 ALL, 5 of 6 AML, 1 of 1
lymphoma patients are alive and in remission. This includes eight
of the 19 CBT recipients. The regimen of TBI, F and M allows the
engraftment of allogeneic HSC (including mismatched unrelated
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